

肿瘤预防与治疗 ZHONGLIU YUFANG YU ZHILIAO

月刊

2022 年

第 35 卷

第 9 期

2022 年 9 月 25 日出版

主 管

四川省卫生健康委员会

主 办

四川省肿瘤医院

协 办

四川省抗癌协会

编辑出版

《肿瘤预防与治疗》编委会

地址: 成都市武侯区人民南路

四段 55 号

邮政编码: 610041

电话: 028-85420233

传真: 028-85420115

E-mail: zlyfyzl@163.com

网址: www.zlyfyzl.cn

主 编 郎锦义

广告经营许可证号

5100004000310

印 刷

成都市新都华兴印务有限公司

发 行

四川省报刊发行局

订 阅

全国各地邮局

邮发代号: 62-142

定 价

每册 15.00 元 全年 180.00 元

中国标准连续出版物号

ISSN 1674-0904

CN 51-1703/R

本刊刊出的所有文章不代表《肿瘤预防与治疗》杂志编委会的观点,除非特别声明。

2022 年版权归《肿瘤预防与治疗》

编委会所有

本刊如果有印刷装订质量问题请向本刊编辑部调换

目 次

肿瘤免疫治疗专题

——本期执行主编:周进

专家述评

肿瘤放疗联合免疫治疗之回顾与展望

犟伟奇,许文婧,王佩,孙建国 (775)

基础研究

IL-6 致非小细胞肺癌 PD-1 抑制剂治疗抵抗的效应和机制研究

张衡,卢从华,赵茜,罗诺,李鑫,王任源,赵呈龙,王治国,祝梦晓,封明霞,何勇,李力 (782)

不同免疫细胞及 PD-1 单抗杀伤前列腺癌细胞的初步研究

王丙萍,段金凯,高艳伟,马虎林,苏日娜,张浩,高维实 (790)

临床研究

老年晚期非小细胞肺癌患者免疫治疗的疗效和安全性

陈靖宇,张欢,夏杨晨,刘芳芳,蒋继宗,朱正飞,胡洁,褚倩 (800)

免疫治疗在中国人非小细胞肺癌患者早期临床应用阶段的疗效和安全性研究

麦秀芝,胡皓,曹亚兵 (812)

晚期非小细胞肺癌患者外周血程序性死亡受体 1 和程序性死亡受体配体 1 的表达及临床意义

戴凡,罗文,夏航彪,邓燕,肖情,邱容 (817)

临床经验与技术交流

EGFR 敏感突变晚期肺腺癌患者靶向耐药后的免疫治疗:疗效和毒性分析

朱敏,谢肖肖,田雨可,曾梓洵,胡瀚,贾蓉,周进 (822)

免疫治疗在宫颈癌合并甲状腺 MALT 淋巴瘤中的应用 1 例并文献复习

高煜欣,李睿,龙宇,李娇,唐建宁,谭蕊蓉,卢进 (829)

免疫热点研究进展

免疫检查点抑制剂相关性肝毒性的研究进展

白怡雪,袁瑞,张师容,郭卉,刘梦洁 (835)

肿瘤新抗原免疫治疗的研究进展

王倩倩,毕纹玫,魏阳,冯燮林,蒋文军,吴少波 (842)

肿瘤免疫治疗假进展

王泽文,孙美丽 (848)

特定瘤种免疫治疗前沿

放疗联合免疫治疗在不可切除局部晚期及晚期肺癌中的应用进展

刘青,蒲丹,吴强,李燕 (854)

靶向联合免疫治疗在不可切除肝细胞癌的临床研究进展

李蓝星,张音洁,金永东 (861)

复发/难治弥漫性大 B 淋巴瘤免疫治疗进展

万梦迪,洪煌明 (875)

个案

尼达尼布治疗放射性肺炎合并免疫检查点抑制剂相关性肺炎 1 例

高源,刘青,李燕 (882)

·读者·作者·编者·

《肿瘤预防与治疗》文章荐读 (874)

本期责任编辑:李娟

英文编辑:钟若冰

期刊基本参数:CN51-1703/R * 1973 * m * 16 * 116 * zh+en * P * ¥15.00 * 1000 * 15 * 2022-09

JOURNAL OF CANCER CONTROL AND TREATMENT

Vol. 35 No. 9 September 25, 2022 (Monthly)

Supervisor

Health Commission of Sichuan Province

Sponsor

Sichuan Cancer Hospital

Cooperator

Sichuan Anti-Cancer Association

Editorial Office & Publisher

Editorial Board of Journal of Cancer
Control and Treatment

55, 4th Section, Renmin Road South,
Chengdu 610041, Sichuan, China

Tel: +86-028-85420233

Fax: +86-028-85420115

E-mail: zlyfyzl@163.com

www.zlyfyzl.cn

Editor-in-Chief

Lang Jinyi

Advertising Management License

5100004000310

Printer

Printing Factory of Chengdu Xindu
Huaxin Co. Ltd.

Distributor

Sichuan Post Distributive CO.

Subscription

Local Post Office

RMB ¥15.00 Per Issue

CSSN

ISSN 1674-0904

CN 51-1703/R

All articles published do not reflect
the official policy of the Editorial Board,
unless this is clearly specified.

**Copyright 2022 by the Editorial
Board of Journal of Cancer Control
and Treatment**

CONTENTS IN BRIEF

Special Issue on Cancer Immunotherapy

Managing Editor: Zhou Jin

Expert Review

Review and Prospect of Radiotherapy Combined with
Immunotherapy for Tumors

Nian Weiqi, Xu Wenjing, Wang Pei, Sun Jianguo (775)

Basic Research

Effects and Mechanisms of IL-6-Induced Resistance to PD-1
Inhibitors in Non-small Cell Lung Cancer

*Zhang Heng, Lu Conghua, Zhao Qian, Luo Nuo, Li Xin, Wang Renyuan,
Zhao Chenglong, Wang Zhiguo, Zhu Mengxiao, Feng Mingxia, He Yong,
Li Li* (782)

Preliminary Study on the Killing of Prostate Cancer Cells by
Different Immune Cells and PD-1 Monoclonal Antibody

*Wang Bingping, Duan Jinkai, Gao Yanwei, Ma Hulin, Su Rina, Zhang
Hao, Gao Weishi* (790)

Clinical Research

Efficacy and Safety of Immunotherapy in Elderly Patients
with Advanced Non-small Cell Lung Cancer

*Chen Jingyu, Zhang Huan, Xia Yangcheng, Liu Fangfang, Jiang
Jizong, Zhu Zhengfei, Hu Jie, Chu Qian* (800)

Efficacy and Safety of Immune Checkpoint Inhibitors for
Chinese Non-small Cell Lung Cancer Patients in Initial
Clinical Practice

Mak Saochi, Hu Hao, Cao Yabing (812)

Expressions of PD-1 and PD-L1 in Peripheral Blood of Patients with Advanced Non-small Cell Lung Cancer and Their Clinical Significance

Dai Fan, Luo Wen, Xia Hangbiao, Deng Yan, Xiao Qing, Qiu Rong (817)

Clinical Experience and Technical Exchange

Efficacy and Toxicity of Immunotherapy for EGFR-Positive Advanced Lung Adenocarcinoma Patients after Resistance to Targeted Drugs

Zhu Min, Xie Xiaoxiao, Tian Yuke, Zeng Zixun, Hu Han, Jia Rong, Zhou jin (822)

Immunotherapy in Cervical Carcinoma with Thyroid MALT Lymphoma: A Case Report and Literature Review

Gao Yuxin, Li Rui, Long Yu, Li Jiao, Tang Jianning, Tan Ruirong, Lu Jin (829)

Hotspots of Immunotherapy

Clinical Progress of ICI-Induced Immune-Mediated Hepatitis

Bai Yixue, Yuan Rui, Zhang Shirong, Guo Hui, Liu Mengjie (835)

Research Progress of Neoantigen in Tumor Immunotherapy

Wang Qianqian, Bi Wenmei, Wei Yang, Feng Xielin, Jiang Wenjun, Wu Shaobo (842)

Pseudoprogression of Tumor Immunotherapy

Wang Zewen, Sun Meili (848)

Frontier of Immunotherapy for Specific Tumors

Progress of Radiotherapy Combined with Immunotherapy for Locally Advanced, Unresectable or Metastatic Lung Cancer

Liu Qing, Pu Dan, Wu Qiang, Li Yan (854)

Advances in Targeted Therapy Combined with Immunotherapy for Unresectable Hepatocellular Carcinoma

Li Lanxing, Zhang Yinjie, Jin Yongdong (861)

Progress in Immunotherapy for Relapsed or Refractory Diffuse Large B Lymphoma

Wan Mengdi, Hong Huangming (875)